CTI Biopharma is a Seattle based biopharmaceutical company focused on acquisition, development, and commercialization of novel targeted therapies for blood-related cancers that offer options to patients and healthcare providers. CTI has one FDA-approved product VONJO® (pacritinib). See full prescribing information at www.VONJO.com.
Contact: 3010 Western Avenue, #800 Seattle, WA 98121 800-215-2355